Literature DB >> 15749503

Thermachoice endometrial ablation in the outpatient setting, without local anesthesia or intravenous sedation: a prospective cohort study.

Fiona Marsh1, Jenny Thewlis, Sean Duffy.   

Abstract

OBJECTIVE: To determine whether Thermachoice endometrial ablation (EA) is a safe and acceptable procedure when performed in the outpatient (OP) setting without local anesthesia or IV sedation.
DESIGN: Prospective cohort (double group) study.
SETTING: Hysteroscopy clinic of large UK hospital. PATIENT(S): Twenty-seven women with menorrhagia. INTERVENTION(S): The first cohort of women underwent Thermachoice EA without elective analgesia. The second cohort underwent Thermachoice after taking ibuprofen. MAIN OUTCOME MEASURE(S): To map pain scores and the requirement of "rescue analgesia." To assess speed of recovery and time away from home. RESULT(S): Thermachoice EA was successfully performed in the OP setting on 89% (n = 24) of women. Four women in the first cohort required rescue analgesia compared to none in the second. During the procedure there was little difference between the groups visual analogue style pain scores-with the overall score being 3.6 (range = 0-10). Postoperatively there was a lower mean pain score in the second cohort, with fewer women experiencing nausea and vomiting. Mean time away from home was 2.6 hours and mean time to make a full recovery was 3.3 days. Women required analgesia for 2.6 days, on average, and returned to their normal activities at this time. CONCLUSION(S): Thermachoice EA without local analgesia or IV sedation can be safely and successfully performed in the OP setting and if ibuprofen is taken preoperatively few women require "rescue analgesia."

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15749503     DOI: 10.1016/j.fertnstert.2004.08.030

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  1 in total

1.  Outpatient Thermachoice endometrial balloon ablation: long-term, prognostic and quality-of-life measures.

Authors:  Rajesh Varma; Hemi Soneja; Nadia Samuel; Eki Sangha; Thomas Justin Clark; Janesh K Gupta
Journal:  Gynecol Obstet Invest       Date:  2010-06-16       Impact factor: 2.031

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.